Œ¤‹†‹ÆÑ2011”N

Œ´’˜˜_•¶

  1. Shingo Oda, Miki Nakajima, Yasuyuki Toyoda, Tatsuki Fukami, and Tsuyoshi Yokoi. Progesterone receptor membrane component 1 modulates human cytochrome P450 activities in an isoform-dependent manner. Drug Metab. Dispos., 39: 2057-2065 (2011). [PubMed]
  2. Akinori Nakajima, Tatsuki Fukami, Yuki Kobayashi, Akinobu Watanabe, Miki Nakajima, and Tsuyoshi Yokoi. Human arylacetamide deacetylase is responsible for deacetylation of rifamycins: rifamipicin, rifabutin, and rifapentine. Biochem. Pharmacol., 82: 1747-1756 (2011). [PubMed]
  3. Katsuhiko Kida, Miki Nakajima, Takuya Mohri, Yuki Oda, Shingo Takagi, Tatsuki Fukami, and Tsuyoshi Yokoi. PPARƒ¿ is regulated by miR-21 and miR-27b in human liver. Pharm. Res., 28: 2467-2476 (2011). [PubMed]
  4. Hiroko Hosomi, Tatsuki Fukami, Atsushi Iwamura, Miki Nakajima, and Tsuyoshi Yokoi. Development of a highly sensitive cytotoxicity assay system for CYP3A4-mediated metabolic activation. Drug Metab. Dispos., 39: 1388-1395 (2011). [PubMed]
  5. Tomomi Hioki, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi. Human paraoxonase 1 is the enzyme responsible for pilocarpine hydrolysis. Drug Metab. Dispos., 39: 1345-1352 (2011). [PubMed]
  6. Toru Usui, Takanori Hashizume, Takashi Katsumata, Tsuyoshi Yokoi, and Setsuko Komuro. In vivo investigation of the glutathione S-transferase M1 and T1 null genotypes as risk factors for troglitazone-induced liver injury. Drug Metab. Dispos., 39: 1303-1310 (2011). [PubMed]
  7. Yasuyuki Toyoda, Taishi Miyashita, Shinya Endo, Koichi Tsuneyama, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi. Estradiol and progesterone modulate halothane-induced liver injury in mice. Toxicol. Lett., 204: 17-24 (2011). [PubMed]
  8. Atsushi Iwamura, Tatsuki Fukami, Hiroko Hosomi, Miki Nakajima, and Tsuyoshi Yokoi. CYP2C9-mediated metabolic activation of losartan detected by a highly sensitive cell-cased screening assay. Drug Metab. Dispos., 39: 838-846 (2011). [PubMed]
  9. Yuko Abe, Ryoichi Fujiwara, Shingo Oda, Tsuyoshi Yokoi, and Miki Nakajima. Interpretation for the effects of protein kinase C inhibitors on human UDP-glucuronosyltransferase 1A (UGT1A) proteins in cellulo. Drug Metab. Pharmacokinet, 26: 256-265 (2011). [PubMed]
  10. Satonori Higuchi, Masanori Kobayashi, Yukitaka Yoshikawa, Koichi Tsuneyama, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi. IL-4 mediates dicloxacillin-induced liver injury in mice. Toxicol. Lett., 200: 139-145 (2011). [PubMed]
  11. Toshihisa Koga, Ryoichi Fujiwara, Miki Nakajima, and Tsuyoshi Yokoi. Toxicological evaluation of acyl glucuronides of NSAIDs using HEK293 cells stably expressing human UGT and human hepatocytes. Drug Metab. Dispos., 39: 54-60 (2011). [PubMed]
  12. Shin-ichi Yokota, Eriko Higashi, Tatsuki Fukami, Tsuyoshi Yokoi, and Miki Nakajima. Human CYP2A6 is regulated by nuclear factor-erythroid 2 related factor 2. Biochem. Pharmacol., 81: 289-294 (2011). [PubMed]
  13. Katsuhiko Mizuno, Yasuyuki Toyoda, Tatsuki Fukami, Miki Nakajima, and Tsuyoshi Yokoi. Stimulation of pro-inflammatory responses by mebendazole in human monocytic THP-1 cells through an ERK signaling pathway. Arch. Toxicol., 85: 199-207 (2011). [PubMed]

‘à

  1. Tsuyoshi Yokoi and Miki Nakajima. Toxicological implications of modulation of gene expression by microRNAs. Toxicol. Sci., 123F1-14 (2011). [PubMed] [Cover]
  2. Miki Nakajima and Tsuyoshi Yokoi. MicroRNAs from biology to future pharmacotherapy: regulation of cytochrome P450s and nuclear receptors. Pharmacol. Ther., 131:330-337 (2011). [PubMed]
  3. ’†“‡@”ü‹I.@–ò•¨“®‘Ô‚ÆmicroRNA,@ƒtƒ@ƒ‹ƒ}ƒVƒA, 47: 141-145@(2011).

’˜‘

  1. ‰¡ˆä@‹B. ‘æII‘Š‘ãŽÓ‚Ì•]‰¿‚Æ‘n–ò@uˆã–ò•iŠJ”­‚É•K—v‚ȃXƒgƒ‰ƒeƒW[ãv“ú–{–ò—Šw‰ï•Ò, 224-231 (2011).